Braidwell’s Vir Biotechnology VIR Stock Holding History

Braidwell’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-728,549	Closed	-$17.9M	–	95
2023 Q2	$17.9M	Buy	728,549 +124,513	+21%	+$3.13M	0.58%	57
2023 Q1	$14.1M	Buy	+604,036	New	+$15.4M	0.46%	61

Other funds holding VIR

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Braidwell's VIR Position: Q3 2023 in Review

Braidwell sold out of Vir Biotechnology (VIR) in Q3 2023, closing a stake of 728,549 shares — an estimated $17.9M sold.

Braidwell first reported a position in VIR in Q1 2023 and held it in 2 quarters. The position peaked at $17.9M in Q2 2023. 214 funds tracked by Wall St. Rank hold VIR as of Q3 2023.

Braidwell reported no remaining Vir Biotechnology position as of Q3 2023 after selling out during the quarter.
Braidwell sold 728,549 Vir Biotechnology shares in Q3 2023, an estimated $17.9M.
Braidwell first reported a position in Vir Biotechnology in Q1 2023 and held it in 2 quarters.
Braidwell's Vir Biotechnology position peaked at $17.9M in Q2 2023.
214 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2023.

Based on Braidwell's 13F filing for Q3 2023, filed 14 Nov 2023.